Amplicor

Amplicor

A proprietary–Roche Diagnostics PCR-based test used to monitor HIV-1 viral load
References in periodicals archive ?
2] reported that the Amplicor HIV-1 DNA PCR test (Roche Molecular Systems, Branchburg, NJ, USA) did not detect all subtypes with equivalent sensitivity and that 10% of the non-subtype B samples tested negative.
Laboratories used the following methods for analysis: 290 laboratories reported using Digene Hybrid Capture 2 (HC2, Qiagen); 143 laboratories used Cervista (Hologic); 42 laboratories used Third Wave Invader (Third Wave Technologies, Madison, Wisconsin); 8 participating laboratories used Roche AMPLICOR (Roche Diagnostics, Basel, Switzerland); 8 laboratories used Access Genetics (Access Genetics, Minneapolis, Minnesota); 5 laboratories used Roche Linear Array Linear Assay/Line Probe (Roche Diagnostics); 27 laboratories used laboratory-developed tests; 37 laboratories used other commercial kits; and 19 used other (noncommercial) methods.
The NAAT instrumentation systems that are in use include the Roche cobas 4800 and the Roche cobas Amplicor platforms, BD Viper, and the Abbott M2000 platform.
Explain the methodology of the COBAS AMPLICOR CT/NG assay.
Comparison of Roche Cobas Amplicor Mycobacterium tuberculosis Assay with In-House PCR and culture for detection of M.
An aliquot of each sample was processed with the Amplicor PCR test (Roche Molecular Systems, Branchburg, NJ, USA) for detection of C.
AMPLICOR (Roche Molecular Systems, Alameda, CA): The Roche AMPLICOR HPV test amplifies target DNA by PCR followed by nucleic-acid hybridization to various HPV types.
This was followed by genomic DNA extraction from the discs followed by amplification and detection using the Roche Amplicor HIV-1 DNA assay version 1.
5 showed that a Lower Limit Of Detection (LOD) of 360 copies could be obtained when 200 micro litre of EDTA or Heparin plasma was spotted on a filter paper and the correlation with plasma tested directly with the COBAS Amplicor test was excellent (R=0.
The FDA approves a supplement to the Amplicor HIV-1 Monitor Test, extending the lower limit of viral load quantification from 400 to 50 copies/mL.
Marketed by Roche Diagnostics, the Amplicor HCV Test, version 2.